GenSpera’s first drug, G-202, targets PSMA Enzyme, found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer. G-202 is currently in phase 1 safety trials at the University of Wisconsin Carbone Cancer Center (Madison, Wisconsin), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, and the Cancer Therapy & Research Center at the University of Texas Health Science Center of San Antonio, at San Antonio, Texas.
At the completion of this multi-center trial, GenSpera expects to move on to Phase 2 trials possibly in prostate, stomach and other cancers, all with the same drug, G-202.
In the case of GenSpera’s second drug, G-115, its target is PSA, an enzyme found only in prostate cancer tumors.
